Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

IIDEAYA Biosciences, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
I

IDEAYA Biosciences, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    Sep 25, 2026Investor Relations | IDEAYA Biosciences
  • IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
    Sep 9, 2026Investor Relations | IDEAYA Biosciences
  • IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
    Sep 1, 2026Investor Relations | IDEAYA Biosciences
  • IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
    Aug 31, 2026Investor Relations | IDEAYA Biosciences
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    Aug 28, 2026Investor Relations | IDEAYA Biosciences
  • IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
    Aug 19, 2026Investor Relations | IDEAYA Biosciences
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$39.71Close ยท Sep 22, 2026